Dr Aristides Tagalakis is a Reader in Gene Delivery and Nanomedicine at Edge Hill University. The main objective of his research has been the development and implementation of innovative non-viral and nanoparticle technologies in gene therapy for solid tumours, cystic fibrosis, glaucoma, neurological and cardiovascular disorders. These have included a variety of somatic gene transfer approaches towards the efficient, widespread and long-term expression of recombinant genes locally or systemically, silencing of disease-implicated genes, as well as gene repair/editing.

Previously he worked as a Research Fellow and then a Senior Research Fellow at UCL, where he is now an Associate Professor. He holds a PhD from The University of London. He has authored over 90 peer-reviewed publications (original research articles and conference proceedings) in high-impact international journals. He is a member of the ‘Nanoagents and Synthetic Formulations Scientific Committee’ of the American Society of Gene and Cell Therapy. He is a reviewer of national and international project/programme grants and a regular reviewer of over 50 leading scientific journals. He serves on editorial boards of scientific journals. He is a Fellow of: the Institute of Biomedical Sciences, the Royal Society of Biology, the British Society for Nanomedicine and the Higher Education Academy. He is also a Full Member of the Biochemical Society, the Oligonucleotide Therapeutics Society and the American Society of Gene and Cell Therapy.